COMPASS Pathways (CMPS) to Release Quarterly Earnings on Thursday

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) is scheduled to announce its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.60) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03). During the same quarter last year, the firm posted ($0.62) EPS. On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

COMPASS Pathways Stock Down 2.3 %

Shares of COMPASS Pathways stock traded down $0.15 during trading on Friday, hitting $6.28. 2,385,953 shares of the stock traded hands, compared to its average volume of 552,141. The stock has a market cap of $429.43 million, a P/E ratio of -2.71 and a beta of 2.26. The company has a fifty day moving average price of $6.76 and a two-hundred day moving average price of $7.20. The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.03 and a current ratio of 12.03. COMPASS Pathways has a twelve month low of $5.01 and a twelve month high of $12.75.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CMPS shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $23.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, September 10th. Canaccord Genuity Group decreased their price objective on COMPASS Pathways from $50.00 to $48.00 and set a "buy" rating for the company in a research note on Friday, August 2nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of COMPASS Pathways in a report on Monday, September 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $120.00 price objective on shares of COMPASS Pathways in a research report on Friday, August 23rd. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $47.40.

Insider Transactions at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the company's stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the transaction, the insider now directly owns 6,905,774 shares of the company's stock, valued at $41,779,932.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 4.25% of the stock is currently owned by corporate insiders.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.